EGETIS THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.96 SEK | +9.09% |
|
+10.83% | +24.73% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,071 | 1,233 | 1,108 | 1,524 | 1,633 | 2,036 | - | - |
| Enterprise Value (EV) 1 | 815.7 | 945.2 | 963.6 | 1,396 | 1,438 | 2,139 | 1,974 | 1,631 |
| P/E ratio | -16.7 x | -2.77 x | -11.2 x | -7.1 x | -4.29 x | -7.33 x | 10.2 x | 7.64 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13 x | 30.3 x | 28.7 x | 67.4 x | 28.3 x | 31.3 x | 4.32 x | 3.14 x |
| EV / Revenue | 9.88 x | 23.2 x | 25 x | 61.8 x | 25 x | 32.9 x | 4.19 x | 2.52 x |
| EV / EBITDA | -12.3 x | -5.31 x | -9.34 x | -7.14 x | -4.48 x | -7.47 x | 14.6 x | 3.97 x |
| EV / FCF | -13 x | -4.87 x | - | -8.05 x | -5.16 x | -6.86 x | -105 x | - |
| FCF Yield | -7.68% | -20.5% | - | -12.4% | -19.4% | -14.6% | -0.95% | - |
| Price to Book | 4.26 x | 1.96 x | 2.1 x | 3.01 x | 2.66 x | 7.18 x | 4.07 x | 2.47 x |
| Nbr of stocks (in thousands) | 53,533 | 165,069 | 165,069 | 214,589 | 292,571 | 292,571 | - | - |
| Reference price 2 | 20.00 | 7.470 | 6.710 | 7.100 | 5.580 | 6.960 | 6.960 | 6.960 |
| Announcement Date | 2/18/20 | 2/17/21 | 2/17/22 | 2/22/23 | 2/22/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 82.56 | 40.66 | 38.54 | 22.6 | 57.6 | 65.08 | 470.9 | 647.8 |
| EBITDA 1 | -66.47 | -178 | -103.2 | -195.4 | -321.2 | -286.4 | 135.6 | 411 |
| EBIT 1 | -66.68 | -178.4 | -105.7 | -198.1 | -324.8 | -288.7 | 133.1 | 411 |
| Operating Margin | -80.76% | -438.73% | -274.19% | -876.55% | -563.89% | -443.66% | 28.27% | 63.45% |
| Earnings before Tax (EBT) 1 | -61.42 | -179.1 | -104.5 | -193.8 | -326.8 | -291.3 | 124.1 | 374.1 |
| Net income 1 | -61.42 | -179.1 | -104.5 | -193.8 | -326.9 | -291.3 | 104.9 | 297 |
| Net margin | -74.4% | -440.51% | -271.23% | -857.52% | -567.53% | -447.65% | 22.27% | 45.85% |
| EPS 2 | -1.200 | -2.700 | -0.6000 | -1.000 | -1.300 | -0.9500 | 0.6836 | 0.9114 |
| Free Cash Flow 1 | -62.64 | -194.2 | - | -173.5 | -278.4 | -312 | -18.8 | - |
| FCF margin | -75.87% | -477.55% | - | -767.7% | -483.33% | -479.41% | -3.99% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/18/20 | 2/17/21 | 2/17/22 | 2/22/23 | 2/22/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.21 | 3.511 | - | 5.023 | 5.1 | 5.7 | 6.8 | 5.9 | 12.2 | 32.6 | 10 | 9 | 10 | 10 |
| EBITDA 1 | -18.92 | -31.95 | - | -34.31 | -54.7 | -77.5 | -74 | -79.4 | -85.6 | -82.2 | -86 | -85 | -85 | -85 |
| EBIT 1 | -19.59 | -32.62 | - | -34.98 | -55.4 | -78.2 | -74.9 | -80.3 | -86.5 | -83.1 | -86 | -85 | -85 | -85 |
| Operating Margin | -315.48% | -929.08% | - | -696.42% | -1,086.27% | -1,371.93% | -1,101.47% | -1,361.02% | -709.02% | -254.91% | -860% | -944.44% | -850% | -850% |
| Earnings before Tax (EBT) 1 | -22.53 | -32.06 | - | -33.24 | -53.9 | -77.8 | -74.9 | -79.5 | -86.2 | -86.1 | -89.35 | -88.43 | -94.29 | -94.59 |
| Net income 1 | -22.53 | -32.06 | -28.82 | -33.24 | -53.09 | -77.8 | -74.9 | -79.5 | -86.2 | -86.3 | -89.35 | -88.43 | -94.29 | -94.59 |
| Net margin | -362.8% | -913.07% | - | -661.84% | -1,040.98% | -1,364.91% | -1,101.47% | -1,347.46% | -706.56% | -264.72% | -893.54% | -982.61% | -942.87% | -945.85% |
| EPS 2 | -0.1000 | -0.2000 | -0.2000 | -0.2000 | -0.3000 | -0.4000 | -0.3000 | -0.3000 | -0.3000 | -0.3000 | -0.3054 | -0.3023 | -0.3223 | -0.3059 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/17/22 | 4/26/22 | 8/19/22 | 11/8/22 | 2/22/23 | 4/26/23 | 8/22/23 | 11/8/23 | 2/22/24 | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 103 | - | - |
| Net Cash position 1 | 255 | 288 | 144 | 128 | 195 | - | 62 | 406 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.3582 x | - | - |
| Free Cash Flow 1 | -62.6 | -194 | - | -174 | -278 | -312 | -18.8 | - |
| ROE (net income / shareholders' equity) | -26.5% | -41% | -18.1% | -37.5% | -62.2% | -71.4% | 42.9% | 38.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 4.700 | 3.810 | 3.190 | 2.360 | 2.100 | 0.9700 | 1.710 | 2.820 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 0.02 | - | - | - | 5 | 8.65 | - |
| Capex / Sales | - | 0.06% | - | - | - | 7.68% | 1.84% | - |
| Announcement Date | 2/18/20 | 2/17/21 | 2/17/22 | 2/22/23 | 2/22/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.96
SEK
Average target price
13.12
SEK
Spread / Average Target
+88.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.73% | 170M | |
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
- Stock Market
- Equities
- EGTX Stock
- Financials Egetis Therapeutics AB
